Adaptimmune Therapeutics plc / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €204.51M +29.0% €33.03M -1,464.4% 16.2% +0.18 pp N/A N/A
    (estimated) €158.53M +43.4% -€2.42M -93.1% -1.5% +0.30 pp N/A N/A
    (estimated) €110.58M +79.5% -€34.87M -48.3% -31.5% +0.78 pp N/A N/A
    (estimated) €61.60M +43.5% -€67.44M -43.1% -109.5% +1.7 pp N/A N/A
    (estimated) €42.93M -72.0% -€118.51M +94.3% -276.1% -2.4 pp N/A N/A
    €153.38M +195.3% -€61.01M -37.8% -39.8% +1.5 pp -€60.73M -48.2% -39.6% +1.9 pp
    €51.94M +122.0% -€98.11M -31.2% -188.9% +4.2 pp -€117.17M +21.4% -225.6% +1.9 pp
    €23.39M +341.5% -€142.55M +4.7% -609.5% +20 pp -€96.52M -674.2% -412.7% -7.3 pp
    €5.30M +55.4% -€136.20M +21.5% -2,571.0% +7.2 pp €16.81M -138.5% 317.3% +16 pp
    €3.41M +252.8% -€112.08M -5.2% -3,286.8% +89 pp -€43.67M -53.7% -1,280.6% +85 pp
    €966.66K -98.1% -€118.17M +43.6% -12,225.0% -120 pp -€94.28M +9.8% -9,753.4% -96 pp
    €51.27M +57.3% -€82.29M +36.2% -160.5% +0.25 pp -€85.88M +240.2% -167.5% -0.90 pp
    €32.59M +166.5% -€60.43M -2.0% -185.4% +3.2 pp -€25.25M -17.2% -77.5% +1.7 pp
    €12.23M +32.4% -€61.67M +231.6% -504.1% -3.0 pp -€30.48M +28.1% -249.2% +0.085 pp
    €9.24M +1,673.2% -€18.60M +70.0% -201.4% +19 pp -€23.80M -171.4% -257.7% -67 pp
    €520.91K +∞% -€10.94M +50.1% -2,100.8% -21 pp €33.33M -608.6% 6,397.5% +64 pp
    €0.00 -€7.29M N/A -€6.55M N/A

    Notifications